POET Technologies launch “lab to fab” revised strategy

POET Technologies {TSX.V: PTK} have filed MD & A documents for the six months ended 30th June 2015.

The board have also announced a revised “lab to fab” plan to commercialise their product range…..


POET Technologies files its Interim Financial Statements and MD&A for the 6 Months ended June 30, 2015.


Toronto, ON, San Jose, CA, and Storrs, CT, August 12, 2015 – POET Technologies Inc. {TSX-V: PTK} and {OTCQX: POETF} – developer of the planar opto-electronic technology (“POET”) platform for monolithic fabrication of integrated circuit devices containing both electronic and optical elements on a single semiconductor wafer, wishes to announce that it has filed today its interim financial statements and MD&A for the six month period ended June 30, 2015.


The documents were approved by the Board of Directors (the “Board”) at its meeting
held on August 10, 2015. At the meeting, the directors were presented with reports from Dr. Suresh Venkatesan, the Company’s new Chief Executive Officer, and Dr. Subhash Deshmukh, the Company’s new Chief Operating Officer. They have been working extremely diligently since their recent appointment to develop a new plan in furtherance of the Company’s transition from lab-to-fab.


The directors were extremely pleased with the early positive progress reported by the new management team. As pointed out in the MD&A: “With an immediate view to commercialisation, the Company has continued to develop the base process technology necessary to build the complete suite of optoelectronics devices. The new management team is focused on exploiting existing high growth markets where the disruptive power of the POET platform IP provides competitive differentiation.”

POET initiates commercialization process of its differentiated technology The core source of technology differentiation has been validated in the laboratory at the University of Connecticut, and with that the Company is positioning itself to take its technology to the commercialization phase.


The Company has, for the first time, engaged commercial epitaxial wafer suppliers in providing wafers with the unique and proprietary POET epitaxial stack. While comprehensive discussions are underway with a number of potential foundry and epitaxial wafer partners, we have recently signed memorandums of understanding with some of these companies and expect to continue this process. This should accelerate the lab-fab transition, utilizing state of the art processes that position the Company for success in defined commercial markets.


We are pleased to be working with well-established companies as both our foundry partners and as suppliers of our proprietary epitaxial wafers”, said Dr. Venkatesan. “We are focused on monetizing the technology in existing and proven high growth markets
where the disruptive technology innovations will provide a relevant and sustained source of competitive differentiation. We will be communicating the vision, objectives and accelerated drive to product realization around the end of September.”
Dr. Taylor’s revised role at POET Technologies to accelerate development of new technology and product applications Dr. Geoff Taylor, the Company’s Chief Scientist, has realigned his role in the Company. Dr. Taylor has resigned as a director and has entered into a new consulting contract to provide the Company with technical and analytic
support on the development of the POET integrated circuit technology platform and its initial products.
“I am thankful to the Board of Directors for its support. I am looking forward to concentrating on my primary mission, the uplifting of POET to a mainstream integrated circuit technology. To this end I will be providing technical input to the Board in the development and expansion of the POET IP platform”, said Dr. Taylor. “Our CEO, Dr. Venkatesan, has joined the Board and has provided new meaningful and exciting ideas for
the deployment of our technology. I will continue to advise the Board and liaise with Suresh on both technology improvement and implementation in new areas of focus. Both Suresh and I are increasingly convinced about the potential and applications of the disruptive POET platform as we set our sights towards commercialisation.”
“Transitioning Board responsibilities to Suresh, allows me to spend more time working on new technology and product applications.”
Dr. Taylor’s innovations and keen insights that have culminated in the POET technology platform, promise to enable disruptions in cost and power over incumbent solutions. I would like to thank Geoff on behalf of the Board for his contributions over the years”, said Dr. Venkatesan. “I look forward to continuing to work with Geoff as we incorporate the technology into products. He will continue to be an active contributor to the development of the technology and products and will be the Chief Technical advisor to and prime source of innovation for the management team.”


About POET Technologies Inc.

POET Technologies is the developer of the POET platform for monolithic fabrication of integrated circuit devices  containing both electronic and optical elements on a single semiconductor wafer.


With head office in Toronto, Ontario, Canada, and operations in San Jose, CA and Storrs, CT, the Company, through ODIS Inc., a U.S. company, designs III-V semiconductor devices for military, industrial and commercial applications, including infrared sensor arrays and ultra-low-power random access memory. The Company has several issued and pending patents for the POET process, with potential high speed and power-efficient applications in devices such as servers, tablet computers and smartphones.


The Company’s common shares trade on the TSX Venture Exchange under the
symbol PTK.V.

For more information please visit our website at



Michel Lafrance, Secretary.
For further information:
Christopher Chu, Taylor Rafferty, LLC
Tel: +1 908 251 9869

Email: poet@taylor-rafferty.com

Head Office: Operations Office:
Suite 501, 121 Richmond St. W P.O. Box 555
Toronto, ON, Canada.

Phone: +1 416 368 9411

Fax:     +1 416 861 0749


M5H 2K1 Storrs-Mansfield, CT 06268

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the  TSX Venture Exchange)  accepts responsibility for the adequacy or accuracy of this release.